GlassScriptPhysician profile
Mickey R Duos
NPI 1922291327
$3,233.47
in general payments reported to CMS, 2019-2025
33 companies · $827 in 2025
The $827 reported for 2025 was more than what 81% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $742 · 2022: $435 · 2023: $893 · 2024: $336 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,962 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,961.77 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $816.34 | 2021-2025 | |
| Glaxosmithkline, LLC. | $381.12 | 2021-2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $219.95 | 2021-2023 | |
| Axsome Therapeutics, INC. | $185.24 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $148.37 | 2022-2025 | Caplyta |
| Dexcom, INC. | $145.38 | 2023-2025 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $145.20 | 2022-2025 | Ibsrela |
| Novo Nordisk INC | $141.15 | 2022-2025 | Ozempic, Rybelsus |
| Endo Pharmaceuticals INC. | $120.03 | 2021 | |
| Antares Pharma, INC. | $106.95 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.35 | 2023-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $77.44 | 2023-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $75.99 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $74.52 | 2022-2025 | Farxiga, Breztri |
| Allergan, INC. | $73.50 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $66.14 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $44.10 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $38.36 | 2021 | |
| Xeris Pharmaceuticals, INC. | $34.42 | 2025 | Gvoke Hypopen |
| Dendreon Pharmaceuticals LLC | $34.30 | 2021 | |
| Janssen Biotech, INC. | $30.14 | 2021 | |
| Vanda Pharmaceuticals INC. | $25.00 | 2025 | Fanapt |
| Alfasigma USA, INC. | $21.50 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.21 | 2022 | |
| Coloplast Corp | $17.23 | 2021 | |
| Vifor Pharma, INC. | $16.65 | 2021 | |
| Corcept Therapeutics | $16.15 | 2025 | Korlym |
| Lundbeck LLC | $15.77 | 2025 | Rexulti |
| Myovant Sciences INC. | $14.66 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.18 | 2021 | |
| Amgen INC. | $12.94 | 2023 | Otezla, Repatha |
| Acerus Pharmaceuticals Corporation | $12.19 | 2021 | |
| Myriad Genetic Laboratories, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mickey Duos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.